Description
This product utilizes CD8+ T cells that have been engineered with our proprietary GeneCircuit technology to specifically target CD22 ( clone I1C1R22-26). We employs the HBV (SV40-BFP-LEF/TCF-EcoRI) vector components and the SynExpress system of the introns Knockout/Positive feedback for a robust and sustained response against cancers.
Host
Human
Target
CD22
Clone
I1C1R22-26
Species Reactivity
Human
Cell Source
Modified CD8+ T cells
Sensor Gene
BFP
Promoter
SV40
Effector Gene
LEF/TCF
Insertion Sites
EcoRI
Gene Modification
Knockout
Modification Domain
Introns
Carrier Type
HBV
Transformation Accuracy
0.89
Cell Culture
Suspension Culture

For Research Use Only | Not For Clinical Use

Online Inquiry
Related Products
Copyright © 2025 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.